Asset profile
AJU-A51
Small molecule
Evidence outlook · lead readout
NCT06329674 · Type 2 Diabetes
The completed lead evidence is positive, with design limits that temper confidence; the rationale below says which.
NCT06329674: The trial was randomized and triple-masked, with 235 participants receiving AJU-A51 or a matched placebo while the other study products were administered according to the assigned regimen. Its primary endpoint was change in HbA1c, a laboratory surrogate measure, and the registry does not report whether the comparison was successful.
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. Pick an indication; Research unlocks the trials, endpoints, key results and grades.
Competitive landscape
60 competitors in this universe: 0 direct rivals (same mechanism and indication), 0 same-class, 60 same-indication; 33 further along in development.
| Drug | Stage | Modality | Mechanism | Evidence signal | Reported efficacygraded featured trials |
|---|---|---|---|---|---|
| AJU-A51: this drug | Phase 3 | Small molecule | SGLT2;DPP-4 | ||
| Afrezza | Approved | Peptide | Insulin receptor (basal), Insulin | ||
| Alogliptin (Nesina) | Approved | Small molecule | DPP-4 | ||
| Bexagliflozin (Brenzavvy) | Approved | Small molecule | SGLT2 | ||
| Canagliflozin (Invokana) | Approved | Small molecule | SGLT2 | ||
| Dapagliflozin (Farxiga / Forxiga) | Approved | Small molecule | SGLT2 | ||
| Dulaglutide (Trulicity) | Approved | Peptide | GLP-1 receptor | ||
| Empagliflozin (Jardiance) | Approved | Small molecule | SGLT2 | ||
| Ertugliflozin (Steglatro) | Approved | Small molecule | SGLT2 | ||
| Glipizide (Glucotrol) | Approved | Small molecule | Sulfonylurea receptor (SUR1) | ||
| Glyburide (Diabeta / Micronase) | Approved | Small molecule | Sulfonylurea receptor (SUR1) | ||
| Insulin Aspart (NovoLog / Fiasp) | Approved | Peptide | Insulin receptor | ||
| Insulin Degludec (Tresiba) | Approved | Peptide | Insulin receptor (basal) | ||
| Insulin Detemir (Levemir) | Approved | Peptide | Insulin receptor (basal) | ||
| Insulin Glargine (Lantus / Toujeo) | Approved | Peptide | Insulin receptor (basal) | ||
| Insulin Glulisine (Apidra) | Approved | Peptide | Insulin receptor (basal) |
…and 45 more. Research shows the complete landscape.
Unlock the full comparison
Research adds each competitor's evidence grade and sourced trial results, aligned per race, so you can see who actually has the data.
Upcoming events
No upcoming readouts on record for this asset.
All registered studies
Every ClinicalTrials.gov study of this drug's own program, grouped by indication and phase. Research unlocks the studies themselves: titles, statuses, dates and featured-trial cross-links.